- Home
- STSS vs GLTO Comparison
STSS vs GLTO Comparison
Compare STSS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- GLTO
- Stock Information
- Founded
- STSS 2017
- GLTO 2011
- Country
- STSS United States
- GLTO Denmark
- Employees
- STSS N/A
- GLTO N/A
- Industry
- STSS Medical/Dental Instruments
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- GLTO Health Care
- Exchange
- STSS Nasdaq
- GLTO Nasdaq
- Market Cap
- STSS 4.6M
- GLTO 4.0M
- IPO Year
- STSS 2022
- GLTO 2020
- Fundamental
- Price
- STSS $5.87
- GLTO $3.29
- Analyst Decision
- STSS
- GLTO Buy
- Analyst Count
- STSS 0
- GLTO 1
- Target Price
- STSS N/A
- GLTO $10.00
- AVG Volume (30 Days)
- STSS 2.6M
- GLTO 86.7K
- Earning Date
- STSS 05-15-2025
- GLTO 05-08-2025
- Dividend Yield
- STSS N/A
- GLTO N/A
- EPS Growth
- STSS N/A
- GLTO N/A
- EPS
- STSS N/A
- GLTO N/A
- Revenue
- STSS N/A
- GLTO N/A
- Revenue This Year
- STSS N/A
- GLTO N/A
- Revenue Next Year
- STSS N/A
- GLTO N/A
- P/E Ratio
- STSS N/A
- GLTO N/A
- Revenue Growth
- STSS N/A
- GLTO N/A
- 52 Week Low
- STSS $3.36
- GLTO $2.01
- 52 Week High
- STSS $2,904.00
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- STSS 42.25
- GLTO 59.33
- Support Level
- STSS $3.44
- GLTO $3.05
- Resistance Level
- STSS $7.04
- GLTO $3.49
- Average True Range (ATR)
- STSS 0.51
- GLTO 0.26
- MACD
- STSS 1.33
- GLTO 0.04
- Stochastic Oscillator
- STSS 67.47
- GLTO 75.76
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.